Catabasis Pharmaceuticals, Inc. (CATB) Analysts See $-0.34 EPS

February 15, 2018 - By Henry Gaston

 Catabasis Pharmaceuticals, Inc. (CATB) Analysts See $ 0.34 EPS

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.34 EPS on March, 15.They anticipate $0.13 EPS change or 27.66 % from last quarter’s $-0.47 EPS. After having $-0.31 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see 9.68 % EPS growth. The stock increased 0.72% or $0.01 during the last trading session, reaching $1.4. About 1.06 million shares traded or 53.18% up from the average. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 73.74% since February 15, 2017 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Coverage

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, November 20 by Citigroup. As per Thursday, October 5, the company rating was maintained by Cowen & Co. Citigroup maintained it with “Buy” rating and $16 target in Tuesday, March 22 report. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Buy” rating given on Monday, August 14 by H.C. Wainwright. Wedbush maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rating on Wednesday, June 8. Wedbush has “Outperform” rating and $17 target. The firm earned “Buy” rating on Thursday, December 22 by H.C. Wainwright. The rating was maintained by Wedbush with “Buy” on Monday, August 17. Oppenheimer maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Monday, August 14 with “Buy” rating. Citigroup maintained the shares of CATB in report on Thursday, October 5 with “Neutral” rating. Cowen & Co maintained it with “Hold” rating and $200 target in Thursday, August 10 report.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $32.32 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

More notable recent Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) news were published by: Seekingalpha.com which released: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q3 2017 Results – Earnings …” on November 10, 2017, also Businesswire.com with their article: “Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to …” published on October 04, 2017, Seekingalpha.com published: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q1 2017 Results – Earnings …” on May 12, 2017. More interesting news about Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) were released by: Seekingalpha.com and their article: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q2 2017 Results – Earnings …” published on August 11, 2017 as well as Seekingalpha.com‘s news article titled: “Catabasis Pharmaceuticals Could Be A Strong Investment Opportunity In 2017” with publication date: April 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.